Hyd varsity startup develops stem cell-based treatment for Covid By IANS | Published on Mon, May 3 2021 22:48 IST | 4 Views University of Hyderabad to allow 2K more students on campus. Image Source: IANS News Hyderabad, May 3 : A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients. Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the Covid-19 'cytokine storm', with significantly improved patient survival and time to recovery.